[{"address1": "630 5th Avenue", "address2": "20th Floor", "city": "New York", "state": "NY", "zip": "10111", "country": "United States", "phone": "844 689 3939", "website": "https://www.anavex.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2001 and is headquartered in New York, New York.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher U. Missling M.B.A., M.S., Ph.D.", "age": 58, "title": "President, CEO, Secretary & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 856100, "exercisedValue": 0, "unexercisedValue": 10940450}, {"maxAge": 1, "name": "Ms. Sandra  Boenisch CPA, CGA", "age": 43, "title": "Principal Financial Officer & Treasurer", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 209527, "exercisedValue": 0, "unexercisedValue": 553580}, {"maxAge": 1, "name": "Dr. Walter E. Kaufmann M.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Clint  Tomlinson", "title": "VP of Corporate", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Adebayo  Laniyonu Ph.D.", "title": "Senior Vice President of Nonclinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edward R Hammond M.D., M.P.H., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kun  Jin Ph.D.", "title": "Head of Biostatistics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Goldberger R.Ph.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Terrie  Kellmeyer Ph.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juan Carlos  Lopez-Talavera M.D., Ph.D.", "title": "Senior VP & Head of Research and Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 4, "compensationRisk": 7, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.84, "open": 8.81, "dayLow": 8.7, "dayHigh": 8.99, "regularMarketPreviousClose": 8.84, "regularMarketOpen": 8.81, "regularMarketDayLow": 8.7, "regularMarketDayHigh": 8.99, "payoutRatio": 0.0, "beta": 0.801, "forwardPE": -14.206349, "volume": 347300, "regularMarketVolume": 347300, "averageVolume": 1106067, "averageVolume10days": 1172390, "averageDailyVolume10Day": 1172390, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 761324544, "fiftyTwoWeekLow": 3.25, "fiftyTwoWeekHigh": 14.441, "fiftyDayAverage": 8.7346, "twoHundredDayAverage": 7.67395, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 640549568, "profitMargins": 0.0, "floatShares": 82257080, "sharesOutstanding": 85064200, "sharesShort": 24588383, "sharesShortPriorMonth": 23444371, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.2891, "heldPercentInsiders": 0.030439999, "heldPercentInstitutions": 0.35364, "shortRatio": 21.81, "shortPercentOfFloat": 0.2981, "impliedSharesOutstanding": 85064200, "bookValue": 1.305, "priceToBook": 6.8582377, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -46491000, "trailingEps": -0.55, "forwardEps": -0.63, "lastSplitFactor": "1:4", "lastSplitDate": 1444176000, "52WeekChange": 1.4320652, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 8.95, "targetHighPrice": 46.0, "targetLowPrice": 15.0, "targetMeanPrice": 34.33333, "targetMedianPrice": 42.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 120775000, "totalCashPerShare": 1.42, "totalDebt": 0, "quickRatio": 9.395, "currentRatio": 9.449, "returnOnAssets": -0.24337, "returnOnEquity": -0.37722, "freeCashflow": -22235500, "operatingCashflow": -35614000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "AVXL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1744924835, "regularMarketTime": 1744920001, "exchange": "NMS", "messageBoardId": "finmb_13580387", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.24434, "regularMarketPrice": 8.95, "shortName": "Anavex Life Sciences Corp.", "marketState": "CLOSED", "postMarketChangePercent": -2.56983, "postMarketPrice": 8.72, "postMarketChange": -0.23, "regularMarketChange": 0.10999966, "regularMarketDayRange": "8.7 - 8.99", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1106067, "fiftyTwoWeekLowChange": 5.7, "fiftyTwoWeekLowChangePercent": 1.753846, "fiftyTwoWeekRange": "3.25 - 14.441", "fiftyTwoWeekHighChange": -5.491, "fiftyTwoWeekHighChangePercent": -0.38023683, "fiftyTwoWeekChangePercent": 143.20653, "earningsTimestamp": 1739363400, "earningsTimestampStart": 1746621000, "earningsTimestampEnd": 1747053000, "earningsCallTimestampStart": 1739367000, "earningsCallTimestampEnd": 1739367000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.55, "epsForward": -0.63, "epsCurrentYear": -0.65, "priceEpsCurrentYear": -13.769231, "fiftyDayAverageChange": 0.21539974, "fiftyDayAverageChangePercent": 0.024660517, "twoHundredDayAverageChange": 1.2760496, "twoHundredDayAverageChangePercent": 0.16628328, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "longName": "Anavex Life Sciences Corp.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1154525400000, "displayName": "Anavex Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]